机译:患有晚期癌症和不同程度的肝功能障碍患者Belinostat的I期药代动力学研究
Early Clinical Trials Development Program Developmental Therapeutics Clinic Division of Cancer;
Cancer Therapeutics ProgramUPMC Hillman Cancer CenterPittsburgh PA USA;
Division of Cancer Treatment and DiagnosisNational Cancer InstituteBethesda MD USA;
Cancer Therapeutics ProgramUPMC Hillman Cancer CenterPittsburgh PA USA;
University Hospitals Seidman Cancer Center and Case Western Reserve UniversityCleveland OH USA;
Early Clinical Trials Development Program Developmental Therapeutics Clinic Division of Cancer;
Cancer Therapy Evaluation Program Division of Cancer Treatment and DiagnosisNational Cancer;
Division of Cancer Treatment and DiagnosisNational Cancer InstituteBethesda MD USA;
Division of Cancer Treatment and DiagnosisNational Cancer InstituteBethesda MD USA;
Wayne State University/Karmanos Cancer InstituteDetroit MI USA;
Montefiore Medical CenterAlbert Einstein College of MedicineNew York NY USA;
University of Colorado Cancer CenterAurora CO USA;
Winship Cancer Institute of Emory UniversityAtlanta GA USA;
City of HopeDuarte CA USA;
Norris Comprehensive Cancer CenterUniversity of Southern CaliforniaLos Angeles CA USA;
Department of Gastrointestinal OncologyMoffitt Cancer Center and Research InstituteTampa FL USA;
Penn State Cancer InstitutePenn State Health Milton S. Hershey Medical CenterHershey PA USA;
Comprehensive Cancer CenterUniversity of California Davis Medical CenterSacramento CA USA;
Carbone Cancer CenterUniversity of WisconsinMadison WI USA;
Early Clinical Trials Development Program Developmental Therapeutics Clinic Division of Cancer;
Division of Cancer Treatment and DiagnosisNational Cancer InstituteBethesda MD USA;
Early Clinical Trials Development Program Developmental Therapeutics Clinic Division of Cancer;
anticancer drugs; drug metabolism; drug safety; histone deacetylase inhibitor; liver disease;
机译:患有晚期癌症和不同程度的肝功能障碍患者Belinostat的I期药代动力学研究
机译:甲磺酸伊马替尼在晚期恶性肿瘤和不同程度的肝功能不全患者中的I期和药代动力学研究:美国国家癌症研究所器官功能障碍工作组的一项研究。
机译:甲磺酸伊马替尼在晚期恶性肿瘤和不同程度的肝功能不全患者中的I期和药代动力学研究:美国国家癌症研究所器官功能障碍工作组的一项研究。
机译:培养HPLC-MS / MS测定以测量血浆中的新型血管生成抑制剂E-3810。癌症患者的初步药代动力学评估
机译:Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
机译:belinostat在晚期癌症和不同程度肝功能不全患者中的I期药代动力学研究
机译:患有晚期癌症和不同程度的肝功能障碍患者Belinostat的I期药代动力学研究